ATE268183T1 - Verwendung von flavolignanen zur herstellung von medikamenten mit antiproliferativer aktivität in gebärmutter,brust,eierstöcken - Google Patents

Verwendung von flavolignanen zur herstellung von medikamenten mit antiproliferativer aktivität in gebärmutter,brust,eierstöcken

Info

Publication number
ATE268183T1
ATE268183T1 AT95935927T AT95935927T ATE268183T1 AT E268183 T1 ATE268183 T1 AT E268183T1 AT 95935927 T AT95935927 T AT 95935927T AT 95935927 T AT95935927 T AT 95935927T AT E268183 T1 ATE268183 T1 AT E268183T1
Authority
AT
Austria
Prior art keywords
silicristin
silidianin
mixtures
effective amount
therapeutically effective
Prior art date
Application number
AT95935927T
Other languages
English (en)
Inventor
Ezio Bombardelli
Paolo Morazzoni
Original Assignee
Indena Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indena Spa filed Critical Indena Spa
Application granted granted Critical
Publication of ATE268183T1 publication Critical patent/ATE268183T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT95935927T 1995-05-23 1995-10-10 Verwendung von flavolignanen zur herstellung von medikamenten mit antiproliferativer aktivität in gebärmutter,brust,eierstöcken ATE268183T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI951047A IT1274549B (it) 1995-05-23 1995-05-23 Uso di flavanolignani per la preparazione di medicamenti ad attivita' antiproliferativa nei tumori dell'utero,dell'ovaio e del seno
PCT/EP1995/003993 WO1996037209A1 (en) 1995-05-23 1995-10-10 Use of flavanolignanes for the preparation of medicaments with antiproliferative activity in uterus, ovary and breast

Publications (1)

Publication Number Publication Date
ATE268183T1 true ATE268183T1 (de) 2004-06-15

Family

ID=11371650

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95935927T ATE268183T1 (de) 1995-05-23 1995-10-10 Verwendung von flavolignanen zur herstellung von medikamenten mit antiproliferativer aktivität in gebärmutter,brust,eierstöcken

Country Status (20)

Country Link
US (2) US5912265A (de)
EP (1) EP0828500B1 (de)
JP (1) JP3178844B2 (de)
KR (1) KR100290030B1 (de)
CN (1) CN1148181C (de)
AT (1) ATE268183T1 (de)
AU (1) AU709802B2 (de)
CA (1) CA2221753C (de)
DE (1) DE69533112T2 (de)
DK (1) DK0828500T3 (de)
ES (1) ES2222466T3 (de)
FI (1) FI119100B (de)
HU (1) HU220627B1 (de)
IT (1) IT1274549B (de)
NO (1) NO317153B1 (de)
PL (1) PL182064B1 (de)
PT (1) PT828500E (de)
RU (1) RU2161488C2 (de)
SI (1) SI0828500T1 (de)
WO (1) WO1996037209A1 (de)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2432560A1 (fr) 1978-08-02 1980-02-29 Texas Instruments Inc Procede de decapage de metaux, en particulier d'aluminium, au plasma de tetrachlorure de silicium
US6379714B1 (en) 1995-04-14 2002-04-30 Pharmaprint, Inc. Pharmaceutical grade botanical drugs
NZ334148A (en) * 1996-08-12 2001-12-21 Celgene Corp 3-Substituted phenyl-ethyl or ethenyl derivatives terminated with a nitrile, alkane, carboxyl or carbamoyl group useful to reduce cytokine levels
US6239114B1 (en) * 1997-09-26 2001-05-29 Kgk Synergize Compositions and methods for treatment of neoplastic diseases with combinations of limonoids, flavonoids and tocotrienols
US6486193B2 (en) 1998-12-31 2002-11-26 Aventis Pharmaceuticals Inc. 3-substituted pyrrolidines useful as inhibitors of matrix metalloproteinases
FR2792846B1 (fr) 1999-04-30 2001-07-27 Salomon Sa Patin a roues en ligne du type a platine superieure articulee
WO2000066232A2 (fr) 1999-04-30 2000-11-09 Salomon S.A. Chassis articule
KR100342942B1 (ko) * 1999-07-05 2002-07-02 민경윤 카르두스 마리아누스 추출물 또는 이로부터 정제된 실리빈을함유하는 경구용 마이크로에멀젼 조성물
WO2001066108A1 (en) * 2000-03-07 2001-09-13 Mucosal Therapeutics Inhibition of ceramide for the prevention and treatment of oral mucositis induced by antineoplastic drugs or radiation
WO2002067853A2 (en) * 2000-10-06 2002-09-06 Probiochem, Llc A combination and method of treatment of hiv and viral diseases, vascular disease and cancer utilizing a cox-2 inhibitor and cystine
WO2002083124A1 (en) * 2000-10-06 2002-10-24 Probiochem, Llc A composition and method of sustaining chemotherapeutic effect while reducing dose of chemotherapeutic agent using cox-2 inhibitor and statin
ATE374609T1 (de) * 2000-11-30 2007-10-15 Childrens Medical Center Synthese von 4-aminothalidomid enantiomeren
US20040092565A1 (en) * 2001-07-25 2004-05-13 George Kindness Composition and method of sustaining chemotherapeutic effect while reducing dose of chemotherapeutic agent using cox-2 inhibitor and statin
EP1314438A1 (de) * 2001-11-23 2003-05-28 Nutricia N.V. Antiproliferative Zusammensetzung
CN1713905A (zh) * 2002-10-15 2005-12-28 细胞基因公司 用于治疗骨髓增生异常综合征的选择性细胞因子抑制药
US7776907B2 (en) * 2002-10-31 2010-08-17 Celgene Corporation Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
NZ540186A (en) * 2002-10-31 2008-03-28 Celgene Corp Composition for the treatment of macular degeneration
US20040091455A1 (en) * 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
MXPA05004777A (es) * 2002-11-06 2005-07-22 Celgene Corp Metodos de uso y composiciones que comprenden farmacos inhibidores selectivos de citocina para el tratamiento y el manejo de padecimientos mieloproliferativos.
EP1581205A1 (de) * 2002-11-18 2005-10-05 Celgene Corporation Verfahren zur verwendung undzusammensetzungen umfassend(+)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamid
NZ540546A (en) * 2002-11-18 2008-03-28 Celgene Corp Methods of using and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
CN100402023C (zh) * 2003-06-21 2008-07-16 山东绿叶天然药物研究开发有限公司 一种水飞蓟素软胶囊及其制备方法
US20080027113A1 (en) * 2003-09-23 2008-01-31 Zeldis Jerome B Methods of Using and Compositions Comprising Immunomodulatory Compounds for Treatment and Management of Macular Degeneration
KR100577514B1 (ko) * 2003-10-21 2006-05-10 한미약품 주식회사 비페닐디메틸디카복실레이트, 및 카르두스 마리아누스추출물 또는 이로부터 정제된 실리빈을 함유하는 경구용마이크로에멀젼 조성물
US20050142104A1 (en) * 2003-11-06 2005-06-30 Zeldis Jerome B. Methods of using and compositions comprising PDE4 modulators for the treatment and management of asbestos-related diseases and disorders
US20060084704A1 (en) * 2004-01-28 2006-04-20 Charles Shih Methods and compositions for enhancing degradation of nuclear receptor transcription factors and uses thereof
AU2005208990A1 (en) * 2004-01-28 2005-08-11 Androscience Corporation Enhancement of anti-androgenic activity by a combination of inhibitors targeting different steps of a steroid-dependent gene activation pathway and uses thereof
US20080213213A1 (en) * 2004-04-14 2008-09-04 Zeldis Jerome B Method For the Treatment of Myelodysplastic Syndromes Using (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione
MXPA06012279A (es) * 2004-04-23 2007-01-31 Celgene Corp Metodos de uso y composiciones que comprenden moduladores de pde4 para el tratamiento y manejo de la hipertension pulmonar.
RU2283658C1 (ru) * 2005-03-29 2006-09-20 Автономная некоммерческая организация Научно-технический центр "Фармбиопресс" Средство и способ лечения и профилактики онкологических заболеваний
RU2292898C1 (ru) * 2005-08-02 2007-02-10 Автономная некоммерческая организация Научно-технический центр "Фармбиопресс" Противоопухолевый липосомный препарат направленного действия
UA91560C2 (ru) 2005-08-31 2010-08-10 Селджин Корпорэйшн Соединения ряда изоиндолимидов, их композиция и применение
RU2306945C1 (ru) * 2006-02-15 2007-09-27 Автономная некоммерческая организация Научно-технический центр "Фармбиопресс" Профилактическая композиция на основе веществ фенольной природы и фосфолипидов
RU2310453C1 (ru) * 2006-02-28 2007-11-20 Автономная некоммерческая организация Научно-технический центр "Фармбиопресс" Способ получения гидрофильного комплекса на основе флавонолигнанов и фосфолипидов
US8877780B2 (en) 2006-08-30 2014-11-04 Celgene Corporation 5-substituted isoindoline compounds
ME02420B (me) 2006-09-26 2016-09-20 Celgene Corp 5-supstituirani derivati kinazolinona kao sredstva protiv raka
MX337906B (es) 2006-10-19 2016-03-28 Signal Pharm Llc Compuestos de heteroarilo, composiciones de los mismos, y su uso como inhibidores de proteina cinasas.
US9000222B2 (en) 2007-01-08 2015-04-07 Androscience Corporation Compounds with (1E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof
AU2008205312B2 (en) * 2007-01-08 2013-11-21 Annji Pharmaceutical Co., Ltd. Compounds with (substituted phenyl)-propenal moiety, their derivatives, biological activity, and uses thereof
US8710272B2 (en) 2007-01-08 2014-04-29 Androscience Corporation Compounds with (1 E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof
US7907654B2 (en) * 2007-04-27 2011-03-15 Hewlett-Packard Development Company, L.P. Laser diode with a grating layer
MX2010001125A (es) 2007-07-31 2010-09-30 Androscience Corp Composiciones incluyendo receptor androgeno de degradacion (ard) ponteciadores y metodos de tratamiento profilactico o terapeutico de trastornos de la piel y la caida de cabello.
CA2704710C (en) 2007-09-26 2016-02-02 Celgene Corporation 6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising the same
US20090298882A1 (en) * 2008-05-13 2009-12-03 Muller George W Thioxoisoindoline compounds and compositions comprising and methods of using the same
CZ2008407A3 (cs) * 2008-06-26 2009-08-26 Agra Group, A. S. Vodorozpustný prípravek na bázi flavanonol lignanu a zpusob jeho prípravy
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
PT2358697E (pt) 2008-10-29 2016-02-03 Celgene Corp Compostos de isoindolina para utilização no tratamento do cancro
RU2379046C1 (ru) * 2008-11-18 2010-01-20 Сергей Викторович Луценко Композиция для терапии патологий печени и онкологических заболеваний
US20120053159A1 (en) 2009-02-11 2012-03-01 Muller George W Isotopologues of lenalidomide
BRPI1007855B1 (pt) 2009-05-19 2020-03-10 Celgene Corporation Formas de dosagem oral compreendendo 4-amino-2-(2,6-dioxopiperidina-3-il)isoindolina-1,3-diona
BR112012015129A2 (pt) 2009-12-22 2019-09-24 Celgene Corp "composto, composição farmacêutica e método para tratar, controlar ou prevenir uma doença ou distúrbio"
PL3202460T3 (pl) 2010-02-11 2019-12-31 Celgene Corporation Pochodne arylometoksyizoindoliny i zawierające je kompozycje oraz sposoby ich zastosowania
US8603527B2 (en) 2010-10-25 2013-12-10 Signal Pharmaceuticals, Llc Pharmaceutical formulations of a substituted diaminopurine
EP2663549B1 (de) 2011-01-10 2018-03-14 Celgene Corporation Phenethylsulfonisoindolinderivate als pde-4- und/oder zytokin-hemmer
WO2012097116A2 (en) 2011-01-14 2012-07-19 Celgene Corporation Isotopologues of isoindole derivatives
DK2683708T3 (da) 2011-03-11 2018-01-29 Celgene Corp Faste former af 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidin-2,6-dion og farmaceutiske sammensætninger og anvendelser deraf
US20140221427A1 (en) 2011-06-22 2014-08-07 Celgene Corporation Isotopologues of pomalidomide
RU2627471C2 (ru) 2011-09-14 2017-08-08 Селджин Корпорейшн Препараты { 2-[(1s)-1-(3-этокси-4-метоксифенил)-2-метансульфонилэтил]-3-оксо-2,3-дигидро-1h-изоиндол-4-ил} амида циклопропанкарбоновой кислоты
RS60415B1 (sr) 2011-12-27 2020-07-31 Amgen (Europe) GmbH Formulacije (+)-2-[1-(3-etoksi-4-metoksi-fenil)-2-metansulfonil-etil]-4-acetil aminoizoindolin-1,3-diona
ES2885769T3 (es) 2012-08-09 2021-12-15 Celgene Corp Una forma sólida de clorhidrato de (s)-3-(4-((4-morpholinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidina-2,6-diona
EP2752201A1 (de) * 2013-01-04 2014-07-09 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. C-terminale HSP90-Hemmer zur Behandlung von Hypophysenadenomen
JP6359563B2 (ja) 2013-01-14 2018-07-18 デュートルクス・リミテッド・ライアビリティ・カンパニーＤｅｕｔｅＲｘ， ＬＬＣ ３−（５置換−４−オキソキナゾリン−３（４ｈ）−イル）−３−ジュウテロピペリジン−２，６−ジオン誘導体
EP2764866A1 (de) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Hemmer der nedd8-aktivierenden Enzyme
US9132117B2 (en) 2013-06-17 2015-09-15 Kgk Synergize, Inc Compositions and methods for glycemic control of subjects with impaired fasting glucose
UA117141C2 (uk) 2013-10-08 2018-06-25 Селджин Корпорейшн Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону
TWI546722B (zh) * 2013-12-11 2016-08-21 新益先創科技股份有限公司 控制點感測面板及控制點感測面板設計方法
TW201540323A (zh) 2014-01-15 2015-11-01 Celgene Corp ３－（５－胺基－２－甲基－４－側氧基－４ｈ－喹唑啉－３－基）－哌啶－２，６－二酮之調配物
US20170172921A1 (en) * 2016-12-14 2017-06-22 Mahmoud Reza Jaafari Polyphenolic compounds encapsualated in long circulating liposomes and use thereof
WO2019233440A1 (zh) * 2018-06-09 2019-12-12 江苏新元素医药科技有限公司 一类用于肝病治疗或预防的化合物
CN109432084A (zh) * 2018-12-26 2019-03-08 温州医科大学 一种抗癌组合物及其在药物制备中的应用
KR102682905B1 (ko) * 2020-10-22 2024-07-08 경희대학교 산학협력단 실리마린 매개된 셀레늄 나노입자 및 이의 용도
CN112494479B (zh) * 2020-12-28 2022-06-21 华中科技大学同济医学院附属同济医院 茶黄素在制备卵巢功能保护药物方面的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1215291B (it) * 1985-07-17 1990-01-31 Inverni Della Beffa Spa Complessi di flavanolignani con fosfolipidi, loro preparazione e relative composizioni farmaceutiche.
GB2261434A (en) * 1991-11-15 1993-05-19 Inverni Della Beffa Spa New radical scavenging and antipoperoxidant flavanolignans their preparation and formulations for therapeutic use
CN1047944C (zh) * 1993-06-26 2000-01-05 曾庆通 一种治疗慢性肝炎的中药胶囊

Also Published As

Publication number Publication date
CN1185112A (zh) 1998-06-17
HUT77966A (hu) 1998-12-28
ITMI951047A0 (it) 1995-05-23
PT828500E (pt) 2004-08-31
KR100290030B1 (ko) 2001-05-15
IT1274549B (it) 1997-07-17
CA2221753A1 (en) 1996-11-28
AU3805195A (en) 1996-12-11
ITMI951047A1 (it) 1996-11-23
WO1996037209A1 (en) 1996-11-28
NO975334D0 (no) 1997-11-20
PL323450A1 (en) 1998-03-30
US6218369B1 (en) 2001-04-17
DE69533112D1 (de) 2004-07-08
NO317153B1 (no) 2004-08-30
CN1148181C (zh) 2004-05-05
DE69533112T2 (de) 2004-10-21
RU2161488C2 (ru) 2001-01-10
NO975334L (no) 1997-11-20
EP0828500A1 (de) 1998-03-18
AU709802B2 (en) 1999-09-09
ES2222466T3 (es) 2005-02-01
US5912265A (en) 1999-06-15
HK1006222A1 (en) 1999-02-19
JPH10511685A (ja) 1998-11-10
SI0828500T1 (en) 2004-10-31
EP0828500B1 (de) 2004-06-02
PL182064B1 (pl) 2001-10-31
DK0828500T3 (da) 2004-08-16
FI119100B (fi) 2008-07-31
FI974268L (fi) 1997-12-02
FI974268A0 (fi) 1997-11-18
HU220627B1 (hu) 2002-03-28
JP3178844B2 (ja) 2001-06-25
KR19990014941A (ko) 1999-02-25
CA2221753C (en) 2001-07-24

Similar Documents

Publication Publication Date Title
ATE268183T1 (de) Verwendung von flavolignanen zur herstellung von medikamenten mit antiproliferativer aktivität in gebärmutter,brust,eierstöcken
IL267381A (en) A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders
BR0209147A (pt) Terapia combinada que usa anticorpos anti-egfr e agentes anti-hormonais
DK1169059T3 (da) Docetaxel i kombination med rhuMAb HER2 til behandling af cancere
NZ592039A (en) Combination therapy for the treatment of ocular neovascular disorders
BR0115109A (pt) Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese
DK0490077T3 (da) Antisense-oligonukleotider til behandling af cancer
ES2177780T3 (es) Medicamentos para el tratamiento de enfermedades autoinmunes usando interferon tau.
KR950002785A (ko) 골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜
IL135335A0 (en) Method for inhibiting or preventing hormone induced adverse effects and novel pharmaceutical compositions comprising carotenoids
MY112405A (en) Method of tumer treatment.
IS6558A (is) Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni
KR960700734A (ko) 사람 암에 대한 시스플래틴/타목시펜 배합 치료(Combination cisplatin/tamoxifen therapy for human cancers)
YU56702A (sh) Korišćenje fsh za lečenje neplodnosti
ES2110057T3 (es) Composicion medicinal que contiene tcf-ii.
PT1007085E (pt) Utilizacao da hormona de crescimento em composicoes para o tratamento da resistencia a insulina no coracao
KR900701311A (ko) 재조합 사람 α-인터페론을 병소내로 투여하여 편평세포 암을 치료하는 방법
BR9812466A (pt) Uso de ifn-alfa e amantadina para o tratamento da hepatite c crÈnica
ATE280584T1 (de) Verwendung von beta interferon zur herstellung eines arzneimittels zur behandlung von ewings sarkom und eoe
UA36093A (uk) Спосіб лікування хронічного бронхіту
DE60121449D1 (de) Behandlung von hepatitis c mit thymosin und pegyliertem interferon

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0828500

Country of ref document: EP